Rockwell Medical is a fully integrated bio pharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis throughout the U.S. and abroad.

The Company’s innovative drug Triferic is designed to prevent and treat iron deficiency anemia in end-stage renal disease patients. Triferic is the only FDA approved drug with the clinical indication to replace iron and maintain hemoglobin. As part of the long-term growth strategy, the company is establishing global partnerships and licensing opportunities for world-wide distribution and sale of all its therapies.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients for intended safe and effective delivery.